(Total Views: 527)
Posted On: 04/21/2024 9:04:54 PM
Post# of 148870
Believe in "meant to be"?
"They created and funded a privately held company, designed to launch a formal clinical trial.
With approximately thirty-five shareholders and his eldest daughter Corinne, who had become a CPA, CytoDyn, Inc. was born."
"There is really only one way to introduce a new medical practice or a drug. The proper and established method is a clinical trial approved and supervised by the US Food and Drug Administration. The process is time consuming and expensive. CytoDyn needed capital."
" The stock of the publicly traded company was a success and began to sell millions of shares in a day. But the clinical trial was never started. The leader of the entrepreneurial group turned out to be a con artist. To protect his discovery and his colleagues, Allen had to get legal."
" With new management, CytoDyn was ready for business as a publicly traded company. Over 10 million dollars was raised in new capital. With the acquisition of Pro 140, a more developed antibody, CytoDyn began a Phase IIB clinical trial. The company reported spectacular results."
" I think the hardest part of the journey has been the realities of the medical industry," said Allen,
"Big Pharma is risk-averse. They are not interested in innovation, but in selling pills. That was the hardest reality."
http://allendallen.com/Memorium-Allen-D-Allen.html
________
The no trial. Similar to our BLA.
Needing funds -- The point made by Dr. J on e-mails.
Allen D. Allen pharma comment about data: Still similar to what Murray said on e-mail about Dr. J & wanting controled data.
This significant Allen D. Allen comment, brings all of everything Leronlimab, to 4/21/2024:
"Big Pharma is risk-averse. They are not interested in innovation but in selling pills. That was the hardest reality."
Rear view hypothetical:
Pharma bought LL during covid. Who's to say LL would have then went the Chronic Inflammation route. The only surety we have is, as of 4/21/2024.
Point being:
We lost the covid war with LL in our war chest. 600k+
But, LL is now for sure, potentially going to improve / save, an infinite number of lives.
The 600k is now an unfortunate "maybe" trade-off, for a sure focus on unlimited indications.
How are we now on the verge of overcoming even Allen D. Allen's long passed comments, into 4/21/2024?
Due to Cytodyn & Dr. J consulting with many KOL's, ironically, during the hold period.
Realizing now is the time to focus on developing under the patents: Chronic Inflammation.
Final key:
Presenting to FDA Leronlimab can be an add-on, to many current drug programs. Not a replacement intent.
In addition to safe, no drug interaction from LL.
Must also give huge, thanks, to all of the posters who pointed out not only the potential of this route, but the significance of it's a route of friendly add-on, upon the Chronic Inflammation press release.
Dr J has a great FDA relationship & stated such.
It's time:
Meant to Be.
"They created and funded a privately held company, designed to launch a formal clinical trial.
With approximately thirty-five shareholders and his eldest daughter Corinne, who had become a CPA, CytoDyn, Inc. was born."
"There is really only one way to introduce a new medical practice or a drug. The proper and established method is a clinical trial approved and supervised by the US Food and Drug Administration. The process is time consuming and expensive. CytoDyn needed capital."
" The stock of the publicly traded company was a success and began to sell millions of shares in a day. But the clinical trial was never started. The leader of the entrepreneurial group turned out to be a con artist. To protect his discovery and his colleagues, Allen had to get legal."
" With new management, CytoDyn was ready for business as a publicly traded company. Over 10 million dollars was raised in new capital. With the acquisition of Pro 140, a more developed antibody, CytoDyn began a Phase IIB clinical trial. The company reported spectacular results."
" I think the hardest part of the journey has been the realities of the medical industry," said Allen,
"Big Pharma is risk-averse. They are not interested in innovation, but in selling pills. That was the hardest reality."
http://allendallen.com/Memorium-Allen-D-Allen.html
________
The no trial. Similar to our BLA.
Needing funds -- The point made by Dr. J on e-mails.
Allen D. Allen pharma comment about data: Still similar to what Murray said on e-mail about Dr. J & wanting controled data.
This significant Allen D. Allen comment, brings all of everything Leronlimab, to 4/21/2024:
"Big Pharma is risk-averse. They are not interested in innovation but in selling pills. That was the hardest reality."
Rear view hypothetical:
Pharma bought LL during covid. Who's to say LL would have then went the Chronic Inflammation route. The only surety we have is, as of 4/21/2024.
Point being:
We lost the covid war with LL in our war chest. 600k+
But, LL is now for sure, potentially going to improve / save, an infinite number of lives.
The 600k is now an unfortunate "maybe" trade-off, for a sure focus on unlimited indications.
How are we now on the verge of overcoming even Allen D. Allen's long passed comments, into 4/21/2024?
Due to Cytodyn & Dr. J consulting with many KOL's, ironically, during the hold period.
Realizing now is the time to focus on developing under the patents: Chronic Inflammation.
Final key:
Presenting to FDA Leronlimab can be an add-on, to many current drug programs. Not a replacement intent.
In addition to safe, no drug interaction from LL.
Must also give huge, thanks, to all of the posters who pointed out not only the potential of this route, but the significance of it's a route of friendly add-on, upon the Chronic Inflammation press release.
Dr J has a great FDA relationship & stated such.
It's time:
Meant to Be.
(2)
(0)Scroll down for more posts ▼
